1） Le DT, Kim TM, Cutsem EV, et al : Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite
instability-high/mismatch repair-deficient metastatic colorectal cancer : KEYNOTE-164. J Clin Oncol 38 : 11-19, 2020
2） Andre T, Shiu K, Kim TW, et al : Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N
Engl J Med 383 : 2207-2218, 2020
3） Yamauchi M, Morikawa T, Kuchiba A, et al : Assessment of colorectal cancer molecular features along bowel subsites
challenges the conception of distinct dichotomy of proximal vs. distal colorectum. Gut 61 : 847-854, 2012
4） Kawakami H, Zaanan A, Sinicrope FA, et al : MSI testing and its role in the management of colorectal cancer. Curr
Treat Options Oncol 16 : 30, 2015
5）
Roth AD, Teipar S, Delorenzi M, et al : Prognostic role of KRAS and BRAF in stage II and III resected colon
cancer : results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28 : 466474, 2009
6） Akagi K, Oki E, Taniguchi H, et al : Real-world data on microsatellite instability status in various unresectable or
metastatic solid tumors. Cancer Sci 112 : 1105-1113, 2021
232
信州医誌 Vol. 71
抗 PD-1抗体薬が長期奏効している転移性大腸癌
7）
Goldstein J, Tran B, Ensor J, et al : Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with
high-level microsatellite instability (MSI-H). Ann Oncol 25 : 1032-1038, 2014
8） Luo C, Cen S, Ding G, et al : Mucinous colorectal adenocarcinoma : clinical pathology and treatment options. Cancer
Commun 39 : 13, 2019
9）
Millen R, Hendry S, Narasimhan V, et al : CD8＋ tumor-infiltrating lymphocytes within the primary tumor of patients
with synchronous de novo metastatic colorectal carcinoma do not track with survival. Clin Transl Immunology 9 : e
1155, 2020
10）
Wu X, Zhang H, Wing Q, et al : PD-1＋CD8＋T cells are exhausted in tumours and functional in draining lymph nodes
of colorectal cancer patients. Br J Cancer 111 : 1391-1399, 2014
11） Wang Z, Tang X, Wu X, et al : Mismatch repair status between primary colorectal tumor and metastatic tumor, a
retrospective consistent study. Biosci Rep 39 : BSR20190730, 2019
12） He WZ, Hu WM, Wang F, et al : Comparison of mismatch repair status between primary and matched metastatic
sites in patients with colorectal cancer. J Natl Compr Canc Netw 17 : 1174-1183, 2019
13） 佐藤公一，児島 洋，松野裕介，他：粘膜下腫瘍の形態を呈したＳ状結腸粘液癌の１例．日消誌 108：88-94，2011
14） Agrawal B, Krantz MJ, Reddish MA, et al : Cancer-associated MUC1 mucin inhibits human T-cell proliferation,
which is reversible by IL-2. Nat Med 4 : 43-49, 1998
15） Irimura T, McIsaac AM, Carlson DA, et al : Soluble factor normal tissues that stimulates high-molecular-weight
sialoglycoprotein production by human colon carcinoma cells. Cancer Research 50 : 3331-3338, 1990
16） Symonds DA, Vickery AL : Mucinous carcinoma of the colon and rectum. Cancer 37 : 1891-1900, 1976
17） Pihl E, Nairn RC, Hughes ESR, et al : Mucinous colorectal carcinoma ; immunopathology and prognosis. Pathology
12 : 439-447, 1980
18） Kufe DM : Mucins in cancer : function, prognosis and therapy. Nat Rev Cancer 9 : 874-885, 2009
19） 松吉隆仁，井上重隆，野口彰子，他：腹膜転移を伴った17歳 MSI-high 直腸癌の１例．日臨外会誌 83；550-556，2022
20） Salman P, Panay S, Fernandez R, et al : Evidence of response to pembrolizumab in a patient with Lynch syndromerelated metastatic colon cancer. Onco Targets Ther 11 : 7295-7300, 2018
21）
中村 学，沖田浩一，柴田 均，他：大動脈周囲リンパ節転移を伴う T1横行結腸癌の１例．日臨外会誌 76：22522256，2015
22） 吉田亮介，宇野 太，山下和城：稀なリンパ節転移形式を示した BRAF 変異型 MSI-high 盲腸癌の１例．日本大腸肛
門病会誌 74：179-183，2021
23） Tran B, Kopetz S, Tie J, et al : Impact of BRAF mutation and microsatellite instability on the pattern of metastatic
spread and prognosis in metastatic colorectal cancer. Cancer 117 : 4623-4632, 2011
（Ｒ 4. 12. 13 受稿；Ｒ 5. 3. 15 受理） No. 4, 2023
233
...
論文の公開元へ
